PReadyPort MDR1


Monolayer assays using transfected MDCKII-MDR1 cells are widely recognzied tools, acknowledged by the FDA, to study the interaction of drugs with the P-pg/MDR1 transporter.

The MDCKII-MDR1 monolayer system is suitable for performing both substrate and inhibition assessments and is often used to model the net transport events of important fluid compartment barrriers in the organism that express P-gp/MDR1 at a high level, such as the blood-brain-barrier and the intestine.

PreadyPort™-MDR1 kits contains 24-insert integrated plates with differentiated MDCKII cells expressing MDR1, as well as the parental cell line.

The innovative shipping medium, preserves the properties of the barrier throughout transportation.

The first member of the PreadyPort™ series, the PreadyPort™-MDR1 kit is revolutionary in providing a ready-to-use tool for MDCKII-MDR1 monolayer assays.
The kit will allow researchers to perform MDR1 interaction studies on monolayers without bothering about cell-line licensing and culturing.

ISO PreadyPort MDR1


  • Differentiated MDCKII-MDR1 barrier (11 days system)
  • Flexibility: the kit can be used up to 7 days after reception.
  • 24 insert-integrated plate format.
  • Up to 4 days of transportation and storage at room temperature in propietary shipping medium.
  • Shipping medium is easy to remove after liquefication at 37ºC
  • Sample Assay Protocol and Plate Layouts.
  • Available under a Limited Single-use License without extra charge.


  • MDR1 substrates assessments (direct transport studies).
  • MDR1 inhibition assessment (drug-drug interactions)
  • Models the net transport events of barriers like the human blood-brain-barrier and the intestine.


  • P-gp has been identified as the transporter protein with the most relevance to drug PK and interactions by regulatory agencies such as the FDA and EMA.
  • All drug candidates need to be screened for in vitro P-gp substrate and inhibition liability for regulatory submissions.
  • Based on this data, decisions are made for clinical trials.


  • P-gp plays an important function in transporter-based drug-drug interactions.
  • In the case of the intestinal epithelia, blood brain, hepatic and renal barrier, P-gp can act as a barrier to absorption and distribute drugs.
  • In the liver or kidney, P-gp functions in biliary or renal excretion.


  • Mandatory for FDA and EMA guidelines.
  • Available on demand.
  • Ready-to-use
  • User-friendly and easy-handling system
  • Adaptable to automation
  • Transporter experiments without in-house cell propagation.
  • Transporter experiments without in-house cell line development, or acquisition.